Grey Matters Health 

$0.3001
13
-$0.03-7.78% 13:30 Today

Statistics

Day High
0.3
Day Low
0.3
52W High
0.64
52W Low
0.2183
Volume
500
Avg. Volume
11,872
Mkt Cap
1.63M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29JulExpected
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Q1 2026
Q2 2026
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-1.24MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGNPF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap31B
Biogen focuses on neurology, a field relevant to Algernon Pharmaceuticals' interest in neurological diseases, making them direct competitors in research and development of treatments.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company has a strong portfolio in neuroscience and psychiatric medications, areas that Algernon Pharmaceuticals is also exploring, positioning them as competitors.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad range of pharmaceutical products, including treatments for conditions that Algernon Pharmaceuticals is targeting, making them competitors in multiple therapeutic areas.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. competes in the development of drugs for diseases that Algernon Pharmaceuticals is also interested in, such as neurological and respiratory diseases.
Novartis
NVS
Mkt Cap286.78B
Novartis AG has a diversified portfolio, including treatments for neurological conditions, directly competing with Algernon Pharmaceuticals' research interests.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. is involved in the development of treatments for viral infections, an area that Algernon Pharmaceuticals has shown interest in, making them competitors.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie Inc. works on neuroscience among other areas, directly competing with Algernon Pharmaceuticals in the development of treatments for neurological conditions.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. has a focus on innovative therapeutics, including areas that overlap with Algernon Pharmaceuticals' interests, positioning them as competitors.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.85B
Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including areas of interest to Algernon Pharmaceuticals, making them indirect competitors.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in various therapeutic areas, including those targeted by Algernon Pharmaceuticals, making them a broad competitor.

About

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Show more...
CEO
Christopher J. Moreau
Employees
5
Country
Canada
ISIN
CA3978841078
WKN
000A429HD

Listings

0 Comments

Share your thoughts

FAQ

What is Grey Matters Health stock price today?
The current price of AGNPF is $0.30 USD — it has decreased by -7.78% in the past 24 hours. Watch Grey Matters Health stock price performance more closely on the chart.
What is Grey Matters Health stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Grey Matters Health stocks are traded under the ticker AGNPF.
Is Grey Matters Health stock price growing?
AGNPF stock has fallen by -3.13% compared to the previous week, the month change is a +2.35% rise, over the last year Grey Matters Health has showed a -37.35% decrease.
What is Grey Matters Health market cap?
Today Grey Matters Health has the market capitalization of 1.63M
When is the next Grey Matters Health earnings date?
Grey Matters Health is going to release the next earnings report on December 18, 2026.
What is Grey Matters Health revenue for the last year?
Grey Matters Health revenue for the last year amounts to 0 USD.
What is Grey Matters Health net income for the last year?
AGNPF net income for the last year is -1.24M USD.
How many employees does Grey Matters Health have?
As of August 18, 2026, the company has 5 employees.
In which sector is Grey Matters Health located?
Grey Matters Health operates in the Health & Wellness sector.
When did Grey Matters Health complete a stock split?
The last stock split for Grey Matters Health was on April 21, 2026 with a ratio of 1:10.
Where is Grey Matters Health headquartered?
Grey Matters Health is headquartered in Vancouver, Canada.